AU2010324506B2 - Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume - Google Patents

Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume Download PDF

Info

Publication number
AU2010324506B2
AU2010324506B2 AU2010324506A AU2010324506A AU2010324506B2 AU 2010324506 B2 AU2010324506 B2 AU 2010324506B2 AU 2010324506 A AU2010324506 A AU 2010324506A AU 2010324506 A AU2010324506 A AU 2010324506A AU 2010324506 B2 AU2010324506 B2 AU 2010324506B2
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
antigen binding
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010324506A
Other languages
English (en)
Other versions
AU2010324506A1 (en
Inventor
Mario Filion
Traian Sulea
Gilles Bernard Tremblay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council Canada
Alethia Biotherapeutics ULC
Original Assignee
National Research Council Canada
Alethia Biotherapeutics ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council Canada, Alethia Biotherapeutics ULC filed Critical National Research Council Canada
Publication of AU2010324506A1 publication Critical patent/AU2010324506A1/en
Application granted granted Critical
Publication of AU2010324506B2 publication Critical patent/AU2010324506B2/en
Assigned to NATIONAL RESEARCH COUNCIL OF CANADA, ALETHIA BIOTHERAPEUTICS ULC reassignment NATIONAL RESEARCH COUNCIL OF CANADA Request to Amend Deed and Register Assignors: ALETHIA BIOTHERAPEUTICS INC., NATIONAL RESEARCH COUNCIL OF CANADA
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2010324506A 2009-11-24 2010-11-24 Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume Active AU2010324506B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26386509P 2009-11-24 2009-11-24
US61/263,865 2009-11-24
PCT/CA2010/001882 WO2011063523A1 (en) 2009-11-24 2010-11-24 Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume

Publications (2)

Publication Number Publication Date
AU2010324506A1 AU2010324506A1 (en) 2012-05-24
AU2010324506B2 true AU2010324506B2 (en) 2015-02-26

Family

ID=44065791

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010324506A Active AU2010324506B2 (en) 2009-11-24 2010-11-24 Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume

Country Status (13)

Country Link
US (3) US8802826B2 (enExample)
EP (1) EP2504363B1 (enExample)
JP (1) JP5816188B2 (enExample)
CN (1) CN102666585B (enExample)
AU (1) AU2010324506B2 (enExample)
CA (2) CA2928846A1 (enExample)
DK (1) DK2504363T3 (enExample)
EA (1) EA034462B1 (enExample)
ES (1) ES2734886T3 (enExample)
HR (1) HRP20191129T1 (enExample)
PT (1) PT2504363T (enExample)
RU (1) RU2627163C2 (enExample)
WO (1) WO2011063523A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
CA2928846A1 (en) * 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
WO2014159775A1 (en) * 2013-03-14 2014-10-02 Teva Pharmaceutical Industries Ltd. Anti-clusterin monotherapy for cancer treatment
CN104267187A (zh) * 2014-10-15 2015-01-07 吉林大学 检测尿液Clusterin含量试纸条的制备及应用
CN105988004B (zh) * 2015-01-30 2017-12-29 江苏众红生物工程创药研究院有限公司 人组织激肽释放酶1胶体金定量检测试纸卡
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
CA3067351A1 (en) * 2017-06-15 2018-12-20 Nai-Kong Cheung Anti-l1-cam antibodies and uses thereof
CN107353341B (zh) * 2017-08-17 2020-03-27 联合益康（北京）生物科技有限公司 一种抗clu抗体及应用、制备方法和试剂盒
US11912772B2 (en) 2018-07-16 2024-02-27 University Of Hawaii Anti-galectin-9 antibody and methods of use thereof
EP4081548A4 (en) * 2019-12-24 2024-07-24 LaNova Medicines Limited Anti-sirp? monoclonal antibodies and uses thereof
CN111808194B (zh) * 2020-07-13 2021-04-20 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
AU2022264619A1 (en) * 2021-04-27 2023-11-30 Alethia Biotherapeutics Ulc Tumor infiltrating lymphocytes therapy
EP4329801A4 (en) * 2021-04-27 2025-05-14 Alethia Biotherapeutics Inc. Method for allowing immune cells infiltration in tumors
EP4475885A4 (en) * 2022-02-07 2026-02-18 Alethia Biotherapeutics Ulc POLYTHERAPY INTENDED FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
WO2025129072A1 (en) * 2023-12-13 2025-06-19 Corbus Pharmaceuticals, Inc. Anti-alpha-v-beta-8 integrin antibodies and uses thereof
IL330302A (en) * 2024-01-10 2026-08-01 Alethia Biotherapeutics Ulc Combination therapy for neoadjuvant cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030930A1 (en) * 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3933850A1 (de) 1989-10-06 1991-04-18 Schering Ag Zytolyse-inhibitor (zli), eine diese blutplasmaprotein kodierende dna-sequenz, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses proteins
ATE204299T1 (de) 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
AU9312598A (en) 1997-09-10 1999-03-29 Allegheny University Of The Health Sciences Inhibitors of collagen assembly
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
WO2000034469A1 (en) 1998-12-11 2000-06-15 The Research Foundation Of State University Of New York At Albany Compositions and methods for altering cell migration
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
CA2402293A1 (en) 2000-03-07 2001-09-13 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001253140A1 (en) 2000-04-03 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Tumor markers in ovarian cancer
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2004521627A (ja) 2001-02-09 2004-07-22 インサイト・ゲノミックス・インコーポレイテッド 細胞増殖、細胞分化および細胞死に関連するタンパク質
CA2443644A1 (en) 2001-04-04 2003-01-16 Elan Corporation, Plc Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
KR100945108B1 (ko) 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
AU2002368077B2 (en) * 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US20030134301A1 (en) 2001-07-27 2003-07-17 Brooksbank Robert Alan Identification and use of molecules implicated in pain
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
US20070082337A1 (en) 2004-01-27 2007-04-12 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003054152A2 (en) 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides
WO2003062421A1 (en) 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
WO2003080640A1 (en) 2002-03-07 2003-10-02 Ludwig Institute For Cancer Research Lymphatic and blood endothelial cell genes
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
US7285541B2 (en) 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
KR101117673B1 (ko) 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
WO2004028479A2 (en) 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
US20050048490A1 (en) 2002-09-26 2005-03-03 Incyte Corp. Proteins associated with cell growth, differentiation, and death
US8722872B2 (en) 2002-10-02 2014-05-13 The University Of British Columbia Compositions and methods for treatment of prostate and other cancers
CA2500687A1 (en) 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
US20040146921A1 (en) 2003-01-24 2004-07-29 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
WO2005049806A2 (en) 2003-03-14 2005-06-02 Nuvelo, Inc. Novel nucleic acids and polypeptides
EP1610810A2 (en) 2003-03-28 2006-01-04 Applied Research Systems ARS Holding N.V. Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
CA2520518A1 (en) 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of angiogenic disorders
US20040220131A1 (en) 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
EP1708961B1 (en) 2003-12-04 2011-03-09 Abbott Biotherapeutics Corp. Anti-ip-10 antibodies
AT412785B (de) 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
GB0329254D0 (en) 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections
GB0329958D0 (en) 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
US7309487B2 (en) 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
ITRM20040098A1 (it) 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
KR20070049637A (ko) 2004-07-09 2007-05-11 트리패스 이미징, 인코포레이티드 난소 질환 검출 방법 및 조성물
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
WO2006037604A1 (en) 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
SI1814595T1 (sl) 2004-11-23 2014-06-30 The University Of British Columbia Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina
WO2006081430A2 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
US7883858B2 (en) 2005-01-27 2011-02-08 Institute For Systems Biology Methods for identifying and monitoring drug side effects
WO2006089586A1 (en) 2005-02-23 2006-08-31 Medizinische Universität Graz Use of a compound with clusterin activity for the treatment of diseases associated with the deposition of abnormal proteins
WO2006096653A2 (en) 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
US20080307537A1 (en) 2005-03-31 2008-12-11 Dana-Farber Cancer Institute, Inc. Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
WO2006113671A2 (en) 2005-04-15 2006-10-26 Oncomethylome Sciences, S.A. Methylation markers for diagnosis and treatment of cancers
WO2007022248A2 (en) 2005-08-16 2007-02-22 Sloan Kettering Institute For Cancer Research Methods of detection of cancer using peptide profiles
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101126423B1 (ko) 2005-10-21 2012-07-11 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
US7972802B2 (en) 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1963534A2 (en) 2005-12-19 2008-09-03 Genizon Biosciences Inc. Genemap of the human gene associated with crohn's disease
CA2634072A1 (en) 2005-12-21 2007-06-28 Universite De Montreal Markers for memory t cells and uses thereof
KR100679173B1 (ko) 2006-02-28 2007-02-06 주식회사 바이오인프라 위암 진단용 단백질 마커 및 이를 이용한 진단키트
MY169492A (en) * 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US20080026485A1 (en) 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2087152B1 (en) 2006-10-27 2015-03-11 Walfish, Paul Endometrial biomarkers
WO2008085024A1 (en) 2007-01-12 2008-07-17 Erasmus University Medical Center Rotterdam Identification and detection of peptides relating to specific disorders
GB0703652D0 (en) 2007-02-26 2007-04-04 Univ Bradford Method for the allosteric modulation of beta1 integrin
WO2009006382A1 (en) 2007-07-02 2009-01-08 Purdue Research Foundation Detection of glycopeptides and glycoproteins for medical diagnostics
WO2009034562A2 (en) 2007-09-11 2009-03-19 Dublin City University A method of assessing lung squamous cell carcinoma status in an individual
US8617877B2 (en) 2007-11-02 2013-12-31 The Johns Hopkins University Cardiac stem cell and myocyte secreted paracrine factors
US7923253B2 (en) 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
EP2071336A1 (en) 2007-12-13 2009-06-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma
WO2009117030A2 (en) * 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
WO2009093246A2 (en) * 2008-01-22 2009-07-30 Compugen Ltd. Novel clusterin derived peptide
WO2009116860A1 (en) 2008-03-17 2009-09-24 Vereniging Het Nederlands Kanker Instituut Markers providing prognosis of metastasis among cancer patients
KR101110758B1 (ko) 2008-06-02 2012-02-15 경북대학교 산학협력단 뇌졸중 표적용 펩티드 및 이의 용도
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
WO2010030980A2 (en) 2008-09-12 2010-03-18 University Of South Florida Akt and clusterin as biomarkers of chemotherapeutic responsiveness
CA2756570C (en) 2009-04-17 2019-04-30 National Research Council Of Canada Peptide ligands for clusterin and uses thereof
CA2928846A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030930A1 (en) * 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity

Also Published As

Publication number Publication date
US20170233487A1 (en) 2017-08-17
US20140302020A1 (en) 2014-10-09
HRP20191129T1 (hr) 2019-09-20
EP2504363B1 (en) 2019-05-08
CA2776513A1 (en) 2011-06-03
AU2010324506A1 (en) 2012-05-24
ES2734886T3 (es) 2019-12-12
JP5816188B2 (ja) 2015-11-18
CA2928846A1 (en) 2011-06-03
US9512211B2 (en) 2016-12-06
US20120282251A1 (en) 2012-11-08
PT2504363T (pt) 2019-08-02
US8802826B2 (en) 2014-08-12
CA2776513C (en) 2017-08-01
CN102666585B (zh) 2015-02-18
EA201390744A1 (ru) 2013-11-29
CN102666585A (zh) 2012-09-12
RU2012126098A (ru) 2013-12-27
WO2011063523A1 (en) 2011-06-03
EA034462B1 (ru) 2020-02-11
DK2504363T3 (da) 2019-07-29
EP2504363A1 (en) 2012-10-03
EP2504363A4 (en) 2013-10-09
RU2627163C2 (ru) 2017-08-03
JP2013511288A (ja) 2013-04-04

Similar Documents

Publication Publication Date Title
CA2776513C (en) Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
US12466894B2 (en) Anti-MUC16 antibodies and uses thereof
EP2220121B1 (en) Axl antibodies
CN102131524B (zh) 成纤维细胞生长因子受体2的单克隆抗体
AU2009321508B2 (en) Antibodies that specifically block the biological activity of a tumor antigen
KR102453227B1 (ko) 항-axl 길항성 항체
US9764042B1 (en) Methods of making DLL3 antibody drug conjugates
EA035852B1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
US20180319875A1 (en) Novel anti-nodal antibodies and methods of using same
KR20220143552A (ko) 암 치료 방법 및 조성물
WO2018142323A1 (en) Anti-psma antibodies and uses thereof for diagnostic and therapeutic applications
US20150152193A1 (en) Axl antibodies
NZ626513B2 (en) Anti-cd98 antibodies and methods of use thereof
BR112017019978B1 (pt) Anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, polinucleotídeo, vetor, célula microbiana transgênica ex vivo, método para produzir uma célula transgênica ex vivo, método para produzir um anticorpo, composição farmacêutica e uso do anticorpo

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
GM Mortgages registered

Name of requester: IBC GENERIUM LLC

GMD Discharge of a mortgage

Effective date: 20231108

HB Alteration of name in register

Owner name: NATIONAL RESEARCH COUNCIL OF CANADA

Free format text: FORMER NAME(S): ALETHIA BIOTHERAPEUTICS INC.; NATIONAL RESEARCH COUNCIL OF CANADA

Owner name: ALETHIA BIOTHERAPEUTICS ULC

Free format text: FORMER NAME(S): ALETHIA BIOTHERAPEUTICS INC.; NATIONAL RESEARCH COUNCIL OF CANADA